{"status": "ok", "totalResults": 3, "articles": [{"source": {"id": null, "name": "Investor's Business Daily"}, "author": null, "title": "Futures Mixed; Google Soars On Antitrust Ruling - Investor's Business Daily", "description": "Nvidia broke a key level Tuesday, but gold and biotechs stood out.", "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-google-apple-antitrust-ruling/", "urlToImage": "https://www.investors.com/wp-content/uploads/2021/08/Stock-Google-pie-adobe.jpg", "publishedAt": "2025-09-03T03:13:00Z", "content": "Information in Investors Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. \u2026 [+1064 chars]"}, {"source": {"id": "ars-technica", "name": "Ars Technica"}, "author": "Samuel Axon", "title": "The new Dolby Vision 2 HDR standard is probably going to be controversial - Ars Technica", "description": "It addresses two scourges of modern TV viewing\u2014but maybe not in the way we want.", "url": "https://arstechnica.com/gadgets/2025/09/the-new-dolby-vision-2-hdr-standard-is-probably-going-to-be-controversial/", "urlToImage": "https://cdn.arstechnica.net/wp-content/uploads/2025/09/40b76700-879a-11f0-bdfd-4721c5ffeede-1152x648.jpg", "publishedAt": "2025-09-02T22:52:31Z", "content": null}, {"source": {"id": "ars-technica", "name": "Ars Technica"}, "author": "Beth Mole", "title": "OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial - Ars Technica", "description": "The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.", "url": "https://arstechnica.com/health/2025/09/otc-nasal-spray-seemed-to-cut-covid-infections-by-67-in-mid-sized-trial/", "urlToImage": "https://cdn.arstechnica.net/wp-content/uploads/2025/09/GettyImages-1456826064-2560x1440.jpg", "publishedAt": "2025-09-02T22:36:26Z", "content": null}]}